Plain-English translation of NCT06818149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lung Cancer research guide →This study is looking at heart inflammation that can develop in lung cancer patients receiving immune checkpoint inhibitor therapy. Researchers will collect blood samples from 50 patients—some with mild heart inflammation and some with severe cases—to find biological markers (warning signs in the blood) that can help doctors predict how serious the condition is and what the outcome might be.
Heart inflammation is a known side effect of this type of cancer immunotherapy, but doctors currently have limited tools to quickly determine how serious it is or predict which patients will recover well and which may have complications. This study aims to develop a simple blood test that could help doctors better assess severity and manage the condition more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood samples taken at baseline and then again at 3 days, 7 days, and before you leave the hospital (or at discharge). These samples will be analyzed for heart injury markers, iron metabolism markers, and immune system markers. You'll also be asked to provide information about your symptoms, hospital course, and survival at 3 months after enrollment. The entire process is observational—you won't receive a new treatment, but rather the research team will monitor your existing care and use your blood results to develop better prediction models.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China